|
|
 | | | |
- close
- close
- close
- close
QUOTE AND NEWS
FiercePharma
Aug 1
Comment
For a data point on diversification, look no further than Sanofi's ($SNY) new Chattem unit. The French drugmaker snapped up U.S.-based Chattem to fortify its consumer healthcare business, and chief among the new unit's tasks would be the launch...
StreetInsider.com
Feb 2
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/S%26P+Announces+Change+to+US+Index%3A+NTELOS+%28NTLS%29+for+Chattem+%28CHTT%29/5301229.html for the full story.
StreetInsider.com
Jan 28
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Chattem+%28CHTT%29+Reports+Q4+Adj-EPS+of+%241.18/5282541.html for the full story.
Bloomberg
Dec 23
Comment
(Update1) Sanofi-Aventis SA’s $1.9 billion bid
for Chattem Inc., announced this week, was leaked in advance to
two French investors who reaped $4.2 million by making illegal
insider trades, U.S. regulators claimed in a lawsuit.
Clusterstock
Dec 23
Comment
A judge has frozen the assets of two French citizens accused of insider trading.
Nicolas Patrick Benoit Condroyer and Gilles Robert Roger, who reside in Belgium, allegedly used insider information to illegally trade stock in Chattem...
MarketWatch
Dec 23
Comment
Drug stocks edged higher in early trading Wednesday as shares of Sanofi-Aventis continued to climb in the wake of news that it plans to buy consumer products-maker Chattem Inc. for $1.9 billion. The NYSE Arca Pharmaceutical Index rose 0.5% to...
Stock Blog Hub
Dec 23
Comment
Sanofi-Aventis (SNY) has decided to acquire U.S.-based Chattem Inc. (CHTT) for $93.50 per share, or approximately $1.9 billion, to create the world’s fifth-largest consumer healthcare company. The offered price represents a 34% premium over...
Jutia Group
Dec 22
Comment
Sanofi-Aventis SA agreed to buy Chattem (NASDAQ:CHTT) the maker of Gold Bond medicated body powder, for $1.9 billion to enter the U.S. consumer health care market. Sanofi will pay $93.50 per share in cash, which is 34 percent above Chattem’s...
TheStreet.com
Dec 21
Comment
NEW YORK (TheStreet) - - Pfizer's licensing deal and Sanofi's acquisition of Chattem are just what the investment doctor ordered.
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
